RecruitingPhase 2NCT07104331
SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma
Studying Epithelioid hemangioendothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sarcoma Alliance for Research through Collaboration
- Intervention
- nab-Sirolimus(drug)
- Enrollment
- 41 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2029
Study locations (6)
- Stanford University, Stanford, California, United States
- University of Colorado, Aurora, Colorado, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Washington University St. Louis, St Louis, Missouri, United States
- Sloan Kettering Institute for Cancer Research, New York, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07104331 on ClinicalTrials.govOther trials for Epithelioid hemangioendothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06452160A Study of BGC515 Capsules in Subjects With Advanced Solid TumorsBridGene Biosciences Inc.
- RECRUITINGNCT06408441The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano